<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan E Krown, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jasmeet Chadha Singh, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maki, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">June K Robinson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raphael E Pollock, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth H Baldini, MD, MPH, FASTRO</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kaposi sarcoma (KS) is an angioproliferative disorder that requires infection with human herpes virus 8 (HHV-8), also known as Kaposi sarcoma-associated herpes virus (KSHV), for its development [<a href="#rid1">1-3</a>]. KS is classified into four types based on the clinical circumstances in which it develops: classic (the type originally described by Kaposi, which typically presents in middle or old age), endemic (several forms described in individuals from sub-Saharan Africa prior to the acquired immunodeficiency syndrome [AIDS] epidemic), iatrogenic (a type associated with immunosuppressive drug therapy, typically seen in renal allograft recipients), and AIDS associated (epidemic KS). The epidemiologic and clinical aspects of these four types of KS are compared in the table  (<a class="graphic graphic_table graphicRef76370" href="/d/graphic/76370.html" rel="external">table 1</a>). Additionally, an increased number of cases of KS have been reported in men who have sex with men (MSM) without HIV infection [<a href="#rid4">4</a>]. While some have proposed that KS in MSM without HIV infection be recognized as a distinct fifth form of KS [<a href="#rid5">5-8</a>], one may argue that these individuals comprise a subset of classic KS, as the disease typically presents with relatively few lesions and takes an indolent course. (See  <a class="medical medical_review" href="/d/html/7577.html" rel="external">"Primary care of gay men and men who have sex with men"</a>.)</p><p>This review will focus on the clinical presentation, staging, diagnosis, and treatment of classic KS. The epidemiology, risk factors, pathology, and molecular pathogenesis of classic KS are discussed elsewhere, as are AIDS-related KS and iatrogenic KS developing in the setting of immunosuppressive therapy. (See  <a class="medical medical_review" href="/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/8033.html" rel="external">"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment"</a> and  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation", section on 'Kaposi sarcoma'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Classic KS occurs most often in older males of Mediterranean or Central/Eastern European ancestry, in whom the lesions usually occur on the distal extremities, particularly the lower legs and feet (see  <a class="medical medical_review" href="/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis"</a>). Initial lesions may occur in unusual cutaneous locations, however, in the absence of distal extremity involvement [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Skin lesions</span><span class="headingEndMark"> — </span>Classic KS is characterized by the appearance of purplish, reddish blue, or dark brown/black macules, plaques, and nodules on the skin  (<a class="graphic graphic_picture graphicRef81468 graphicRef69584 graphicRef54707" href="/d/graphic/81468.html" rel="external">picture 1A-C</a>). Nodular lesions may ulcerate and bleed easily. The skin lesions range in size from very small to several centimeters in diameter, and they can remain unchanged for months to years, or grow rapidly within a few weeks and disseminate. (See <a class="local">'Natural history'</a> below.)</p><p>The dermatology literature contains reference to at least 10 different morphologic variants of the cutaneous lesions of KS, which are referred to as patch, plaque, nodular, lymphadenopathic (usually in African children), exophytic, infiltrative (the previous two in African adults with endemic KS), ecchymotic, telangiectatic, keloidal, and cavernous or lymphangioma-like variants [<a href="#rid11">11</a>]. Rare cases of apparently "classic" KS with cutaneous and lymphadenopathic features have been described in children outside Africa [<a href="#rid12">12-16</a>], in some cases associated with rare single-gene inborn errors of immunity without generalized immunodeficiency. The cavernous or lymphangioma-like variants are common in classic KS, particularly in the setting of chronic lymphedema. In this variant, lesions develop on the lower extremities that consist of compressible nodules that appear to be fluid-filled cysts. Histologically, lymphangioma-like KS consists of anastomosing networks of smaller, irregular, and compressible dilated lymphatics lined by flat and cytologically banal endothelial cells [<a href="#rid17">17-19</a>]. There are also additional descriptive categories, including hyperkeratotic (verrucous), micronodular, bullous, anaplastic, pyogenic granuloma-like [<a href="#rid20">20</a>], and intravascular KS variants [<a href="#rid21">21</a>].</p><p>There may be accompanying lymphedema of the affected extremity. The lymphedema is not generally associated with the presence of bulky regional nodal disease but, instead, is related to local dermal infiltration and/or dermal lymphatic involvement. (See  <a class="medical medical_review" href="/d/html/755.html" rel="external">"Clinical features and diagnosis of peripheral lymphedema"</a> and  <a class="medical medical_review" href="/d/html/738.html" rel="external">"Clinical staging and conservative management of peripheral lymphedema"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Extracutaneous involvement</span><span class="headingEndMark"> — </span>During the course of the disease (rarely initially [<a href="#rid22">22-24</a>]), mucous membranes of the mouth and gastrointestinal tract, and regional lymph nodes may be affected. Gastrointestinal tract involvement is usually asymptomatic, but bleeding, diarrhea, protein-losing enteropathy, intussusception, and perforation have been reported [<a href="#rid25">25,26</a>]. In general, gastrointestinal tract/oral mucosal involvement is less common than with acquired immunodeficiency syndrome (AIDS)-related KS, affecting ≤10 percent of patients [<a href="#rid27">27-29</a>]. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment"</a>.)</p><p>However, in one report, an extraordinary 82 percent of Greek patients (71 of 87) with biopsy-proven classic KS who were investigated with upper gastrointestinal endoscopy had gastrointestinal lesions; all 71 had stomach lesions, 19 had esophageal lesions, 8 had lesions of the proximal duodenum, and 2 had both esophageal and duodenal lesions [<a href="#rid30">30</a>]. Although this finding could be interpreted as suggesting the need for screening endoscopy in patients with newly diagnosed classic KS, it also supports the view that the presence of asymptomatic gastrointestinal involvement probably has little effect on prognosis. In practice, routine endoscopy is not performed in people diagnosed with classic KS who do not have symptoms referable to the gastrointestinal tract.</p><p>Regional nodal involvement is relatively uncommon, and it is rarely bulky. Nodal involvement was reported in 15 percent of 66 Greek patients with classic KS in one study [<a href="#rid27">27</a>]. The presence of nodal disease probably does not worsen overall prognosis, although this has been demonstrated in AIDS-related KS, not classic KS. Rare cases of isolated lymph node involvement with classic KS have been described [<a href="#rid31">31</a>].</p><p>Involvement of visceral organs other than the lining of the alimentary tract (eg, lung, liver, bone, bone marrow) is extremely rare [<a href="#rid27">27,32-34</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>In most cases, classic KS has a chronic, indolent course, and it rarely influences survival. Given the affected age group, death from unrelated causes is more common [<a href="#rid35">35-37</a>]. As an example, in a series of 438 American patients with classic KS who were followed for an average of 4.8 years, 24 percent died of second malignancies, 22 percent died of other medical conditions, and only 2 percent died of widespread disease [<a href="#rid38">38</a>].</p><p>Yet, the disease occasionally has an acute onset and a rapidly progressive course, or previously indolent disease can undergo sudden worsening, leading to disability and even death [<a href="#rid35">35,36,39,40</a>]. In fact, Kaposi's original 1872 paper described the disease as "incurable and deadly," stating that "the disease leads to death, and it does so within a short period of two to three years" [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS AND STAGING</span><span class="headingEndMark"> — </span>The diagnosis of classic KS is usually suspected based on the appearance of the characteristic lesions (purplish, reddish blue, or dark brown/black patches, plaques, or nodules) and their distribution (on the skin, most often of the lower extremities).</p><p class="headingAnchor" id="H7"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>In the lower extremity, the lesions can be mistaken for the skin lesions of peripheral vascular disease, a condition that is common in the older adult patients who are at greatest risk for classic KS. (See  <a class="medical medical_review" href="/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease"</a>.)</p><p>Other lesions that may mimic the appearance of classic KS include bacillary angiomatosis and other infections, angiosarcoma, and benign vascular lesions, such as hemangiomas. </p><p>Bacillary angiomatosis is caused by the <em>Bartonella</em> species, a slow-growing, fastidious, gram-negative bacillus, and is readily treated with antibiotic therapy. The skin lesions of bacillary angiomatosis usually appear as numerous, small, red to purple papules that may gradually expand into large pedunculated lesions or nodules that may become friable. The rash may be associated with symptoms such as fever, chills, malaise, headache, and anorexia. <em>Sporothrix schenckii</em> (sporotrichosis) and <em>Mycobacterium marinum</em> skin infections could also be confused with the nodular form of KS. (See  <a class="medical medical_review" href="/d/html/5517.html" rel="external">"Bartonella quintana infections: Clinical features, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/2457.html" rel="external">"Clinical features and diagnosis of sporotrichosis"</a> and  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a>.)</p><p>A variety of less common dermatologic lesions may also be mistaken for classic KS [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Biopsy is required for definitive diagnosis. In addition to observing typical histologic features on standard microscopy, polymerase chain reaction can be performed on the skin lesions to detect amplified human herpes virus 8 (HHV-8) DNA sequences, and immunohistochemical staining of biopsy specimens can also be performed to detect the presence of HHV-8 latency-associated nuclear antigen (LANA-1) within the spindle cells, thus confirming the diagnosis. (See  <a class="medical medical_review" href="/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Radiographic evaluation</span><span class="headingEndMark"> — </span>Asymptomatic patients with classic KS rarely require radiographic evaluation of the affected extremity because of the chronic, usually indolent course. Screening for distant organ involvement is not needed due to the low frequency of radiographically evident metastatic disease. When present, mucosal involvement of the gastrointestinal tract is not generally visible on radiographic studies. As noted above, patients with symptoms referable to the gastrointestinal tract should be considered for endoscopy to evaluate for visceral mucosal involvement. In the absence of symptoms, we do not routinely work patients up for visceral disease based on the status of the cutaneous disease.</p><p class="headingAnchor" id="H10"><span class="h2">Staging</span><span class="headingEndMark"> — </span>In contrast to acquired immunodeficiency syndrome (AIDS)-related KS, there is no commonly used or universally agreed upon staging system for classic KS. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Staging system'</a>.)</p><p>The most recent American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system for soft tissue sarcomas of the extremity and trunk specifically excludes both classic and AIDS-related KS [<a href="#rid42">42,43</a>]. Given the variable natural history of classic KS, one group of investigators used their experience with 300 classic KS patients to derive a proposed staging system based on disease distribution and the clinical pace of progression [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I (maculonodular stage)</strong> – Small macules and nodules primarily confined to the lower extremities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II (infiltrative stage)</strong> – Plaques mainly involving the lower extremities, sometimes associated with a few nodules.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III (florid stage)</strong> – Multiple angiomatous plaques and nodules involving the lower extremities that are often ulcerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IV (disseminated stage)</strong> – Multiple angiomatous nodules and plaques extending beyond the lower extremities.</p><p></p><p>Stage I to III disease was further subdivided into slow (group A) or rapid disease progression (group B, defined as an increase in the total number of plaques/nodules or in the total area of plaques in the three months following an examination); all patients with stage IV disease were considered to have rapidly progressive disease.</p><p>In the original series of 300 patients, those classified as having stage I or II disease had a slower rate of progression, fewer complications, and a lower occurrence of gastrointestinal tract/visceral involvement. In contrast, patients with stage III or IV disease had more rapid disease progression and a greater likelihood of gastrointestinal tract/visceral involvement, local complications, and functional impairment. Rapid evolution was prevalent in the florid and disseminated stages (92 and 100 percent, respectively) and less frequent in the infiltrative and maculonodular stages (42 and 21 percent, respectively). Visceral involvement occurred only in patients with stage IIIB and IV disease (1.2 and 24 percent, respectively). Survival for the four groups was not reported.</p><p>The authors proposed using this classification scheme to select patients with the most aggressive natural history (ie, those with stages IIB, III, and IV disease) for systemic therapy. However, this staging system is not in widespread use. It is based on subjective rather than objective classification of the extent of disease, and its prognostic value has not been independently validated. Furthermore, its predictive value for response to systemic therapy has not been addressed.</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H3570822940"><span class="h2">Overview of the general approach to treatment</span><span class="headingEndMark"> — </span>Given the absence of treatments capable of eradicating latent human herpes virus 8 (HHV-8) infection, one can question whether any form of KS, including classic KS, can be considered "curable." Nonetheless, a number of strategies have been used to manage classic KS, with the major therapeutic goals of achieving symptom palliation, alleviating lymphedema, improving function, decreasing the size of cutaneous or visceral lesions, and delaying or preventing disease progression.</p><p>With relatively few exceptions, the published literature on treatment of classic KS consists of retrospective series and case reports. Prospectively designed phase II trials are scarce, usually include relatively few patients, and do not use standardized objective methods to document response. Furthermore, with a single exception [<a href="#rid45">45</a>], there are no prospectively randomized trials that compare different treatments for classic KS, making it impossible to identify the "best" approach. This is not surprising given the relative scarcity of the disease, the advanced age of many affected individuals, and the frequent presence of comorbidities that may limit treatment options and the ability to participate in clinical trials.</p><p>As an example, one retrospective review of 160 adult patients diagnosed with either classic (131 patients) or endemic (African; 29 patients) KS was conducted at a single dermato-oncology center [<a href="#rid46">46</a>]. At median follow-up of approximately five years, no treatment was required in 14 percent of patients, whereas local or systemic treatments were administered in 45 and 41 percent, respectively. Risk factors that were significantly associated with initiation of systemic therapy included endemic versus classic KS (hazard ratio [HR] 3.29), greater than 10 skin lesions (HR 3.64), visceral KS (HR 2.11), head or neck lesions (HR 2.21), presence of edema (HR 2.18), and delayed diagnosis (ie, time between first symptoms and diagnosis &gt;1 year; HR 2.70). Similar response rates and durations were seen between patients with classic or endemic KS and between those who received systemic chemotherapy or interferon alfa. It should be noted, however, that precise criteria for initiation of systemic therapy, and the choice of therapeutic modality, were not described.</p><p>Despite the limitations described above, some general principles have emerged about classic KS treatment based on empirical evidence; the following represents our general approach to treatment:</p><p class="bulletIndent1"><span class="glyph">●</span>Observation without specific treatment is an option for patients who have a limited number of asymptomatic lesions that do not impair function, although disease progression eventually occurs in most patients. In a study of 39 patients with asymptomatic lesions who were observed without specific treatment, only 34 percent remained progression free at two years [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms related to limited lower extremity edema can be alleviated in many patients with elastic compression stockings [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When treatment is indicated, there are a variety of local and systemic tumor-directed therapy options, the choice of which depends on the extent, location, and pace of disease. Because many active treatments have been described, therapeutic choices are often made based on the experience and medical discipline of the treating clinician, but they also include consideration of patient preferences and comorbid conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of regional nodal disease does not necessarily influence the choice of local versus systemic treatment. Unless the nodal disease is large and symptomatic (an uncommon scenario), we treat these patients based on the volume and extent of their local skin disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no consensus as to the indications for systemic therapy. We consider this approach in (but not limited to) the following situations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic visceral or mucosal involvement (although rare).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse symptomatic lesions on multiple body parts that are not easily encompassed in a single or a limited number of radiation fields.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extensive nodular disease or diffuse involvement of a large portion of an extremity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bulky disease in a localized area of one limb that cannot be encompassed within a single radiation therapy (RT) port.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe associated lymphedema beyond what can be controlled with elastic stockings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with an indication for chemotherapy and without cardiac contraindications, we suggest initial therapy with <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> (PLD). (See <a class="local">'Pegylated liposomal doxorubicin'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with an indication for chemotherapy and a cardiac contraindication to PLD, we offer initial therapy with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> as an alternative to PLD, extrapolating from data supporting the use of paclitaxel in AIDS-related Kaposi sarcoma. (See <a class="local">'Paclitaxel'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those with more limited disease, <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> is an alternative option to chemotherapy. (See <a class="local">'Initial therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with disease progression on initial therapy with either PLD or <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> and who retain adequate performance status, options for subsequent-line chemotherapy include a single-agent taxane (eg, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>), oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (alone or in combination with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>), <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>. For patients with indolent disease progression after initial treatment with chemotherapy, pomalidomide is an alternative for subsequent-line therapy. (See <a class="local">'Subsequent therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individual patients may also be suitable candidates for investigational approaches such as HIV protease inhibitors, mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors, molecularly targeted antiangiogenic agents (eg, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>), and immune checkpoint inhibitor immunotherapy. In our view, these approaches are best considered in the context of a clinical trial. (See <a class="local">'Investigational therapies'</a> below.)</p><p></p><p class="bulletIndent1">There is a need for prospectively defined studies that use well-defined response criteria to better define optimal treatment(s) for classic KS.</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Options for local control</span><span class="headingEndMark"> — </span>There are several options for local control directed at specific lesions or groups of lesions. There is no consensus on the optimal tumor-directed therapy for different classic KS manifestations. Because many active treatments have been described, therapeutic choices are often made based on the experience and medical discipline of the treating clinician, but they also include consideration of patient preferences and comorbid conditions.</p><p class="headingAnchor" id="H13"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>In some cases, if there is a single symptomatic lesion (eg, bleeding or chafing against clothing), excision alone may provide sustained local tumor control [<a href="#rid35">35,36,49</a>], but new lesions commonly develop at other sites. Curettage of single KS nodules followed by topical application of <a class="drug drug_general" data-topicid="113931" href="/d/drug information/113931.html" rel="external">hydrogen peroxide</a> (to achieve hemostasis) is a safe, effective, and simple method for lesion control [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>All forms of KS, including classic KS, are very sensitive to RT. However, because of the multifocal nature of the disease, the persistence of HHV-8 even with successful local lesion control, and the tendency for new lesions to develop in nonirradiated areas, there is no consensus as to the place of RT in the therapeutic armamentarium (particularly when to choose RT over systemic therapy) or as to the optimal RT technique. One scenario in which RT might be chosen is if there were multiple lesions in a confined anatomic area, whereas one might be less inclined to use RT if there were one or a few lesions or if they were widely scattered.</p><p>Several successful strategies have been described [<a href="#rid35">35,51-61</a>]. High rates of tumor regression are reported using different energy sources (cobalt-60, low-energy electrons, superficial X-rays) to deliver local (or, occasionally, extended-field) RT. There is marked variation in total RT doses (6 to 60 Gy) and in fractionation regimens, which range from doses of 6 to 12 Gy in a single fraction to larger total doses administered in smaller fractions over several weeks [<a href="#rid35">35,51,52,54-58,61</a>]. One of the most commonly prescribed regimens is 30 Gy in 15 daily 2 Gy fractions [<a href="#rid59">59,60</a>].</p><p>Although durable local lesion control and symptom relief can be achieved in over 90 percent of cases, most publications do not clearly address the frequency of out-of-field recurrences and the eventual need for additional local or systemic therapy. Treatment of solitary lesions as they arise may require irradiation of numerous adjacent fields and can lead to dosimetric problems at junction points. For this reason, although overall response rates are similar, some authors prefer a strategy of subtotal-skin electron beam therapy over local involved-field RT because of the lower out-of-field recurrence rates [<a href="#rid53">53</a>]. One other frequently employed technique is treatment of the involved portion(s) of the feet and lower extremities (when extensively involved) using a water bath technique, which allows homogeneous radiation of a complex target. In one series using a split-course technique delivering 30 Gy in 10 fractions, disappearance of lesions was seen in 89 percent of patients, although limb edema only regressed in 57 percent [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Cryotherapy and laser therapy</span><span class="headingEndMark"> — </span>As with acquired immunodeficiency syndrome (AIDS)-related KS [<a href="#rid63">63</a>], liquid nitrogen cryotherapy is sometimes used (mainly by dermatologists) for local control of small classic KS lesions [<a href="#rid64">64,65</a>]. However, the effect is mainly cosmetic, and there is no information on the impact of this form of local therapy on long-term disease control. Laser therapy may also be useful for selected cases [<a href="#rid66">66-68</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Intralesional therapy</span><span class="headingEndMark"> — </span>In our experience, intralesional injections, while capable of eradicating injected tumors, can be painful and lead to local scarring; we generally do not use this for treatment of classic KS. However, others have described the associated pain as tolerable, and some authors consider the best candidates for intralesional therapy to be patients with nodular classic KS without visceral involvement and with fewer than 10 lesions on acral sites [<a href="#rid69">69</a>]. The role of electrochemotherapy is unclear. </p><p>Intralesional injection of chemotherapy (most often <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, but sometimes <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> or other agents) leads to local regression of cutaneous KS lesions [<a href="#rid69">69-71</a>]. Case reports have also described a high response rate in single nodular classic KS lesions treated with intralesional <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid71">71</a>] or <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid72">72</a>]. </p><p>Although the characteristics of patients most likely to benefit from intralesional therapy have not been systematically studied, some authors consider the best candidates for intralesional chemotherapy to be patients affected by nodular classic KS without visceral involvement and with fewer than 10 lesions on acral sites [<a href="#rid69">69</a>].</p><p>Intralesional injection of interferon alfa-2a has also been reported to induce regression of classic KS lesions [<a href="#rid73">73</a>]. However, this treatment is unlikely to be practical for individuals with multiple cutaneous lesions as it requires multiple weekly injections over several months.</p><p>Electrochemotherapy uses a small electric current (electroporation, a form of electromotive drug administration) to increase drug delivery into the tumor; this approach has been used primarily with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>. In one series of 23 patients with classic KS treated with this approach, all patients showed tumor regression, which was complete in 65 percent [<a href="#rid74">74</a>]. It should be noted, however, that general or spinal anaesthesia was required to administer the treatment. A similar response rate was noted in a series of 19 patients with stage I or II KS (according to the staging system described by Brambilla et al [<a href="#rid44">44</a>]) [<a href="#rid75">75</a>], and in another series of 18 patients, it was reportedly accompanied by a reduction of the HHV-8 viral load [<a href="#rid76">76</a>]. In the latter study, however, two patients with rapidly progressive disease failed to respond to electrochemotherapy.</p><p class="headingAnchor" id="H17"><span class="h3">Topical therapy</span><span class="headingEndMark"> — </span>The literature is very limited on the benefits of topical therapy for classic KS. While there are no comparator trials, this approach could potentially be considered for patients with a limited number of lesions confined to a relatively small anatomic site who place a high value on avoiding the side effects of more conventional therapy, such as systemic chemotherapy or RT, or for whom other treatment approaches are contraindicated. The optimal agent is not established.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cis-retinoic acid</strong> – <a class="drug drug_general" data-topicid="9366" href="/d/drug information/9366.html" rel="external">Alitretinoin</a> (9-cis-retinoic acid) gel 0.1% is a US Food and Drug Administration (FDA)-approved topical treatment for cutaneous AIDS-associated KS, but published experience in classic KS is limited. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Local symptomatic therapy'</a>.)</p><p></p><p class="bulletIndent1">A single case report of an older adult patient with classic KS noted a good local response, with partial or complete resolution of multiple treated cutaneous lesions, although the patient continued to develop new lesions in untreated skin [<a href="#rid77">77</a>]. Of note, another case report described the failure of <a class="drug drug_general" data-topicid="9366" href="/d/drug information/9366.html" rel="external">alitretinoin</a> gel in a patient with classic KS [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imiquimod</strong> – A prospective clinical trial of topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> demonstrated an objective response (complete or partial) in 47 percent of 17 patients with non-AIDS-related KS [<a href="#rid79">79</a>]. Response was assessed at only one point (36 weeks), and the duration of disease control was not reported. There was an inverse association between lesion area and response. A single case report described complete regression of extensive classic KS using topical imiquimod with occlusive dressings [<a href="#rid80">80</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timolol</strong> – A few small case series note regression of classic KS lesions treated with topical <a class="drug drug_general" data-topicid="9997" href="/d/drug information/9997.html" rel="external">timolol</a>, a nonselective beta-adrenergic antagonist [<a href="#rid81">81-83</a>]. The use of such agents in KS is of interest given the clinical efficacy of oral and topical <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>, another beta blocker, in the treatment of infantile hemangioma, a benign condition that, similar to KS, is characterized by abnormal angiogenesis. (See  <a class="medical medical_review" href="/d/html/5792.html" rel="external">"Infantile hemangiomas: Management"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">Propranolol</a>'s clinical efficacy in infantile hemangioma, together with the proangiogenic effects of catecholamine signaling [<a href="#rid84">84</a>], prompted investigation of its potential anti-KS activity in an in vitro model of KS and led to the demonstration that propranolol treatment diminished the proliferative advantage conferred on endothelial cells by infection with Kaposi sarcoma-associated herpes virus (KSHV) [<a href="#rid85">85</a>], an effect that may be mediated via downregulation of vascular endothelial growth factor (VEGF) [<a href="#rid86">86</a>], an important driver of endothelial cell proliferation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>silver nitrate</strong> – A report described local control of 10 of 11 soft, fungating, and/or oozing classic KS tumors after cauterization with <a class="drug drug_general" data-topicid="9888" href="/d/drug information/9888.html" rel="external">silver nitrate</a> sticks [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nicotine</strong><strong> patches</strong> – Based on the observation that smoking was associated with a reduced risk of classic KS, and the potential effects of nicotine both on immune function and vasoconstriction, a randomized, placebo-controlled trial of dermal nicotine patches was conducted in classic KS [<a href="#rid88">88</a>]. Treatment was well tolerated, but there were no significant effects on classic KS lesions, or on HHV-8 antibody titers or DNA levels in peripheral blood mononuclear cells [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis", section on 'Smoking'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapamycin</strong> – A single case report described KS regression after 16 weeks of topical treatment with rapamycin (<a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>) [<a href="#rid89">89</a>]</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Advanced disease</span></p><p class="headingAnchor" id="H1959072102"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>No cytotoxic chemotherapeutic agents have been approved in the United States or elsewhere specifically for treatment of classic KS, although a number of drugs approved for treatment of AIDS-associated KS or other neoplasms have activity against classic KS, either as initial chemotherapy or, in some cases, after failure of prior therapy. These include PLD, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (alone or in combination with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>), oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid35">35,37,45,90-105</a>]. </p><p><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> does have regulatory approval in the United States for the treatment of both classic KS and AIDS-related KS. (See <a class="local">'Pomalidomide'</a> below and  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Indolent disease (pomalidomide)'</a>.)</p><p class="headingAnchor" id="H19"><span class="h4">Pegylated liposomal doxorubicin</span><span class="headingEndMark"> — </span>In patients with an indication for chemotherapy (ie, general, widespread, bulky, or rapidly progressive classic KS, particularly when it interferes with function or is associated with moderate to severe symptomatic edema or visceral organ involvement) and without cardiac contraindications, we suggest initial therapy with PLD, a drug approved in the United States for AIDS-related KS. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Liposomal doxorubicin (preferred)'</a>.)</p><p>We usually treat with one or two courses of chemotherapy beyond a stable maximal response and gradually stretch out the intervals between treatments. If there is no evidence of progression, we attempt to discontinue therapy and closely monitor, offering retreatment with the same regimen at the time of progression. Although systemic therapy has the potential to cause regression at all disease sites, the optimal duration of chemotherapy has not been systematically studied.</p><p>The benefit of initial treatment with PLD (20 mg/m<sup>2</sup> every three weeks) was addressed in a retrospective multi-institutional series of 55 patients with classic KS [<a href="#rid37">37</a>]. A complete (absence of detectable lesions for at least eight weeks) or major response (≥50 percent decrease in the number of measurable lesions, and absence of new cutaneous lesions for at least eight weeks) was noted in 71 percent. The median time to response was four months, and the median response duration was 25 months.</p><p class="headingAnchor" id="H728434758"><span class="h4">Paclitaxel</span><span class="headingEndMark"> — </span>Extrapolating from data supporting the use of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> in AIDS-related KS, we offer paclitaxel as an alternative to PLD in patients with an indication for chemotherapy and a cardiac contraindication to PLD. Although the optimal dose and schedule of paclitaxel administration has not been systematically studied, randomized trial data supporting the use of paclitaxel in AIDS-related KS suggested better tolerability for an every-three-week dosing schedule of paclitaxel when compared with an every-two-week dosing schedule historically reported in other trials [<a href="#rid106">106,107</a>]. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Paclitaxel'</a> and  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H3691399813"><span class="h4">Pomalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is an acceptable alternative for patients with moderately extensive classic KS confined to the skin or oral cavity, or those with peripheral lymphedema. Pomalidomide has a tolerable toxicity profile and can be given orally [<a href="#rid108">108</a>]. However, some experts may still reasonably offer chemotherapy as initial treatment in these patients, as pomalidomide has only been evaluated in limited numbers of patients and has not been directly compared with chemotherapy in randomized trials. (See <a class="local">'Pegylated liposomal doxorubicin'</a> above.)</p><p>We do <strong>not</strong> offer <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> to those with symptomatic pulmonary or visceral disease, or those with very bulky, ulcerated skin lesions, as pomalidomide has not been evaluated in such patients and further studies are needed to evaluate its clinical efficacy. These patients should be treated initially with chemotherapy in order to achieve immediate and rapid disease response. Additionally, we do not offer pomalidomide to patients with symptomatic peripheral neuropathy, which is a potential side effect. (See <a class="local">'Pegylated liposomal doxorubicin'</a> above and  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Pomalidomide'</a>.)</p><p><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is administered at 5 mg by mouth daily on days 1 through 21 of a 28-day cycle until disease progression or unacceptable toxicity. We suggest the following management strategies:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is associated with teratogenic risk and can only be prescribed through a Risk Evaluation and Mitigation Strategy (REMS) program.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We concurrently administer low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> daily for venous thromboembolism prophylaxis, using a similar approach to patients treated with this agent for multiple myeloma. (See  <a class="medical medical_review" href="/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism", section on 'During maintenance therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific issues regarding the use of <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> in those with baseline kidney impairment and liver disease are discussed separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Pomalidomide'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2837.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Lenalidomide and pomalidomide'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> was investigated in an open-label, single-arm phase I/II trial (12-C-0047) of 28 patients with KS, a majority of whom (75 percent) had previously received chemotherapy [<a href="#rid109">109</a>]. Among the cohort of 10 HIV-negative patients, overall responses were seen in 8 patients (80 percent), including one complete response (10 percent); median duration of response was 10.5 months. Grade ≥3 toxicities included neutropenia (50 percent), decreased phosphate (25 percent), elevated glucose (7 percent), elevated creatinine, rash, diarrhea, and peripheral edema (4 percent each). Neurologic toxicities of pomalidomide are discussed separately. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Pomalidomide'</a>.)</p><p>Based on these results, the FDA granted accelerated approval for <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> in HIV-negative patients with classic KS [<a href="#rid110">110</a>]. Pomalidomide has not been directly compared with other available systemic therapies, and further studies are needed in larger groups of patients to evaluate long-term survival and identify patient subgroups most likely to benefit from this agent.</p><p>The use of <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> in patients with AIDS-related KS is discussed separately. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Indolent disease (pomalidomide)'</a>.)</p><p class="headingAnchor" id="H4103148"><span class="h4">Other agents</span><span class="headingEndMark"> — </span>Other available options for initial therapy in classic KS include <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (alone or in combination with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>), oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>.</p><p>Overall response rates for all of these drugs or drug combinations have been quite high (60 to over 90 percent), and the treatments are generally well tolerated, even in the older adult population at greatest risk for classic KS. Median response durations range from four months to over two years. One retrospective analysis of 32 patients with classic KS treated at a single institution showed that the presence of nodular lesions (versus macular lesions only) was associated with lower progression-free survival after chemotherapy [<a href="#rid111">111</a>].</p><p>In the absence of uniform, prospectively defined, objective criteria for inclusion or for response and progression, and in the absence of randomized trials, it is difficult to make recommendations for preferred treatments on the basis of response rates, duration of benefit, or adverse effects [<a href="#rid112">112</a>]. Only one randomized trial has been conducted in which two different systemic therapies were compared [<a href="#rid45">45</a>]. Sixty-five patients with classic KS were randomly assigned to oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (60 mg/m<sup>2</sup> daily for three days for the first cycle, four days for the second cycle, and five days for the third cycle, as tolerated, with courses repeated every three weeks) or intravenous <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> (3 mg/m<sup>2</sup> weekly for three weeks, then 6 mg/m<sup>2</sup> every three weeks). There were no significant differences between the two treatments with regard to response rate (74 and 58 percent with etoposide and vinblastine, respectively), duration of response, or survival (median not reached in either group with a median follow-up of 38 months). Side effects were infrequent and mild in both groups, although alopecia, nausea, and vomiting (all grade 1 or 2) were more prominent with etoposide, and myelosuppression was more evident with vinblastine (grade 1 in seven, grade 3 in two).</p><p class="headingAnchor" id="H2090733741"><span class="h3">Subsequent therapy</span></p><p class="headingAnchor" id="H4159863701"><span class="h4">Chemotherapy</span><span class="headingEndMark"> — </span>For patients with initial disease progression on PLD and/or <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a>, we offer <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> as subsequent therapy. In a randomized trial of patients with AIDS-related KS, paclitaxel demonstrated a progression-free survival benefit compared with either oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> or the combination of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> plus <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> and was well tolerated [<a href="#rid106">106</a>]. Further details of this study are discussed separately. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Paclitaxel'</a>.)</p><p>Alternative subsequent-line chemotherapy agents also include <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (alone or in combination with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>); oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>; or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>. The choice between these agents must be individualized, taking into account age, comorbidity, and personal preference.</p><p class="headingAnchor" id="H20"><span class="h4">Pomalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is an acceptable alternative for patients with indolent progression after initial chemotherapy. In phase I/II studies of patients with classic KS previous treated with chemotherapy, pomalidomide demonstrated overall response rates of approximately 80 percent [<a href="#rid108">108,109</a>]. Further details regarding pomalidomide are discussed separately. (See <a class="local">'Pomalidomide'</a> above.)</p><p class="headingAnchor" id="H1609153780"><span class="h4">Other immunomodulators</span><span class="headingEndMark"> — </span>Other immunomodulators have been studied in KS, but are not approved by the FDA for patients with classic KS.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalidomide</strong><strong> </strong>– <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">Thalidomide</a>, a prototypic member of a class of medications called immunomodulatory imide drugs, has antiangiogenic, anti-inflammatory, and immunomodulatory effects, similar to IFNa, and the drug is active in AIDS-related KS [<a href="#rid113">113</a>]. Experience with thalidomide is limited in classic KS [<a href="#rid114">114,115</a>]. One report noted activity in three patients with classic KS who received thalidomide 100 mg daily [<a href="#rid114">114</a>]. Two of the three had a complete clinical response after 12 months of treatment. In a second series, 3 of 11 patients with classic KS had a partial response to the same dose of thalidomide [<a href="#rid115">115</a>]. Three patients discontinued drug therapy prematurely due to sensory neuropathy or vertigo. Thalidomide is not an FDA-approved treatment for any form of KS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">Interferon alfa-2b</a><strong> </strong>– Interferon alfa-2b is approved for treatment of AIDS-associated KS in the United States, but has limited availability as the manufacturer has decreased production. While the mechanism of antitumor action of this agent in KS is not known, it may involve direct antiproliferative effects, antiviral effects, inhibition of angiogenesis, and modulation of host cellular and humoral immune responses [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Subsequent therapy'</a>.)</p><p></p><p class="bulletIndent1">There is limited experience with <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> in classic KS. In a prospectively designed phase II clinical trial, 16 patients (13 with classic KS, 3 with endemic African KS), 9 of whom were refractory to chemotherapy and/or RT, were treated with interferon alfa-2b (5 million units subcutaneously three times a week) for a minimum of six months [<a href="#rid117">117</a>]. Major (complete or partial) tumor regressions were observed in 10 patients, and four other patients showed a minor response or stable disease. However, side effects, especially fatigue, low-grade fever, myalgias, and depression, can be prominent</p><p></p><p class="headingAnchor" id="H21"><span class="h3">Investigational therapies</span><span class="headingEndMark"> — </span>For patients with KS, investigational approaches include HIV protease inhibitors, mTOR inhibitors, molecularly targeted antiangiogenic agents (eg, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>), and checkpoint inhibitor immunotherapy. Patients with either HIV related or non-HIV related KS are encouraged to enroll in clinical trials, where available. If proven successful, it is likely that these approaches (with the exception of those specifically targeting HIV infection), would also apply to treatment of classic KS.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV protease inhibitors</strong> – One study attempted to exploit the finding that HIV protease inhibitors exert antiangiogenic and antitumor properties that are distinct from their antiretroviral effects [<a href="#rid118">118</a>]. Sixteen of 28 patients with classic KS who were treated with <a class="drug drug_general" data-topicid="8558" href="/d/drug information/8558.html" rel="external">indinavir</a> were described as having benefits that included a complete response (n = 1), a partial response (n = 2), "improved disease" (n = 5), and stabilization of progressive disease (n = 8). The authors described an association between a favorable clinical course and higher plasma indinavir levels, reduced levels of basic fibroblast growth factor, lower numbers of circulating endothelial cells (a cell type reported to be increased in classic KS [<a href="#rid119">119</a>]), and a reduction in HHV-8 antibody titers. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>mTOR inhibitors</strong> – Case reports describing regression of classic KS in patients treated with the mTOR inhibitor rapamycin (<a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>) [<a href="#rid120">120,121</a>] suggest that this approach, which has proven effective in some cases of transplant-associated KS, may be more generally applicable. Another member of this class of drugs, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, has been used successfully to treat KS in transplant recipients; the reported experience with this agent in classic KS has been scant and mixed [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeted therapies</strong> – Viral genes expressed during the lytic phase of HHV-8 infection may be particularly important in increased expression of growth factors such as VEGF and KIT, which stimulate angiogenesis and activate growth regulatory pathways, such as the phosphoinositide 3-kinase (PI3K) pathway, that lead to dysregulated cell growth. Overexpression of these factors may be exploited as treatment targets. (See  <a class="medical medical_review" href="/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis", section on 'Molecular pathogenesis'</a>.)</p><p></p><p class="bulletIndent1">As an example, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a> is a multitargeted receptor tyrosine kinase inhibitor that inhibits angiogenic pathways through inhibition of various receptor tyrosine kinases, including VEGF receptors 1 and 2; it is approved in the United States for treatment of advanced soft tissue sarcoma and renal cell carcinoma. A single case report describes a patient with classic KS who had an excellent response to low-dose (400 to 800 mg once daily), single-agent pazopanib after failing multiple lines of prior systemic chemotherapy and RT [<a href="#rid123">123</a>]. Although pazopanib is approved in the United States for treatment of advanced soft tissue sarcoma, we still consider its use investigational for classic KS, given the paucity of information on clinical benefit in this patient group. (See  <a class="medical medical_review" href="/d/html/139327.html" rel="external">"Second and later lines of therapy for metastatic soft tissue sarcoma", section on 'Pazopanib'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Checkpoint inhibitor immunotherapy</strong> – The use of checkpoint inhibitor immunotherapy remains investigational in KS, where tumors can express programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), or high tumor mutational burden (TMB). Further prospective clinical trials, especially in those with classic KS, are necessary to determine the optimal immunotherapy regimen as well as predictive markers for treatment response [<a href="#rid124">124-126</a>]. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pembrolizumab</strong> – <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a>, a PD-1 inhibitor, has promising clinical efficacy in patents with KS [<a href="#rid127">127</a>]. As an example, in a single-arm phase II trial of 17 patients with KS (eight with classic and nine with endemic disease) treated with pembrolizumab, the objective response rate was 71 percent, including complete responses in two patients (12 percent) [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents</strong> – Other immunotherapy agents that have been described in observational studies include single-agent <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> [<a href="#rid129">129-131</a>] and nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid132">132,133</a>].</p><p></p><p class="headingAnchor" id="H874427206"><span class="h2">Prevention of infection in sexual partners</span><span class="headingEndMark"> — </span>A common question is the ability of patients with non-HIV HHV-8 KS to transmit the virus and whether there should be any specific precautions taken by patients with non-HIV KS with spouses, significant others, etc. There are no rigorously examined interventions for prevention of HHV-8 infection in the sexual partners of individuals with HHV-8 infection. Saliva is the body fluid that most commonly harbors HHV-8 [<a href="#rid134">134</a>]. It has been suggested that the use of saliva as a sexual lubricant may explain the high rate of HHV-8 infection among men who have sex with men [<a href="#rid135">135</a>]. It is not known whether this has implications for the prevention of HHV-8 transmission among heterosexual adults.</p><p class="headingAnchor" id="H29028513"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83959.html" rel="external">"Patient education: Kaposi sarcoma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Classic Kaposi sarcoma (KS) is a neoplasm characterized by abnormal angiogenesis that requires infection with human herpes virus 8 (HHV-8), along with other cofactors. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Classic KS arises most commonly in older adult males of Mediterranean and Central/Eastern European descent, but it can also occur in younger individuals, in females, and in other geographic areas. (See  <a class="medical medical_review" href="/d/html/7726.html" rel="external">"Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The most common presentation is that of purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the lower extremities, often with lymphedema. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Classic KS is frequently described as slow growing, localized, and indolent, but it can become disseminated and/or grow rapidly, and it can cause significant morbidity and mortality. (See <a class="local">'Natural history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of classic KS requires a biopsy. Involvement of mucous membranes, lymph nodes, and visceral organs is relatively infrequent; radiographic staging evaluation and endoscopic screening are not routinely indicated in asymptomatic patients. (See <a class="local">'Extracutaneous involvement'</a> above and <a class="local">'Radiographic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of asymptomatic or limited disease</strong> – There is no consensus on the optimal tumor-directed therapy for different classic KS manifestations. Because many active treatments have been described, therapeutic choices are often made based on the experience and medical discipline of the treating clinician, but they also include consideration of patient preferences and comorbid conditions.</p><p></p><p class="bulletIndent1">The following represents our general approach:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest observation rather than specific treatment for patients who have a limited number of asymptomatic lesions that do not impair function (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Symptoms related to limited lower extremity edema can be alleviated in many patients with elastic compression stockings. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have limited-volume disease causing symptoms (eg, bleeding or chafing against clothes) or cosmetic disfigurement, we suggest local treatment rather than observation or systemic chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice of modality (radiation therapy [RT], excision, cryotherapy, laser ablation, intralesional or topical therapy) depends on a number of factors, including the site and extent of disease involvement, as well as clinician and patient preference. (See <a class="local">'Options for local control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of symptomatic or diffuse disease</strong> – There is no consensus as to the indications for systemic therapy. We consider this approach in (but not limited to) the following situations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptomatic visceral or mucosal involvement (although rare).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse symptomatic lesions on multiple body parts that are not easily encompassed in a single or a limited number of radiation fields.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extensive nodular disease or diffuse involvement of a large portion of an extremity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bulky disease in a localized area of one limb that cannot be encompassed within a single RT port.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate to severe associated lymphedema beyond what can be controlled with elastic stockings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – For patients with an indication for chemotherapy and without cardiac contraindications, we suggest <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> (PLD) as initial therapy over other available agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Pegylated liposomal doxorubicin'</a> above.)</p><p></p><p class="bulletIndent1">For patients with indication for chemotherapy and a cardiac contraindication to PLD, we offer <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> as an alternative to PLD, extrapolating from data supporting the use of paclitaxel in AIDS-related Kaposi sarcoma. (See <a class="local">'Paclitaxel'</a> above.)</p><p></p><p class="bulletIndent1">For those with more limited disease, <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> is an alternative option to chemotherapy. (See <a class="local">'Pomalidomide'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy</strong> – For patients with disease progression, there are several options for subsequent-line therapy in those who retain an adequate performance status. Available options include a single-agent taxane (eg, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>), oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> or <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> (with or without <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>), <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>. <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">Pomalidomide</a> is an alternative for patients with indolent progression. The decision must be individualized, taking into consideration patient age, accompanying comorbidity, and clinician and patient preference. (See <a class="local">'Subsequent therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational approaches</strong> – Investigational approaches include HIV protease inhibitors, mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors, molecularly targeted antiangiogenic agents (eg, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>), and checkpoint inhibitor immunotherapy. Patients are encouraged to enroll in clinical trials, where available. (See <a class="local">'Investigational therapies'</a> above.)</p><p></p><p class="headingAnchor" id="H4115378495"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas F DeLaney, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335:233.</a></li><li><a class="nounderline abstract_t">Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2:925.</a></li><li><a class="nounderline abstract_t">Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948.</a></li><li><a class="nounderline abstract_t">Friedman-Kien AE, Saltzman BR, Cao YZ, et al. Kaposi's sarcoma in HIV-negative homosexual men. Lancet 1990; 335:168.</a></li><li><a class="nounderline abstract_t">Lanternier F, Lebbé C, Schartz N, et al. Kaposi's sarcoma in HIV-negative men having sex with men. AIDS 2008; 22:1163.</a></li><li><a class="nounderline abstract_t">Rashidghamat E, Bunker CB, Bower M, Banerjee P. Kaposi sarcoma in HIV-negative men who have sex with men. Br J Dermatol 2014; 171:1267.</a></li><li><a class="nounderline abstract_t">Denis D, Seta V, Regnier-Rosencher E, et al. A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris. J Eur Acad Dermatol Venereol 2018; 32:1377.</a></li><li><a class="nounderline abstract_t">Swali R, Limmer A, Tyring SK. Kaposi Sarcoma of the Medial Foot in an MSM, HIV-Negative Man: A Fifth Clinical Variant. J Clin Aesthet Dermatol 2020; 13:42.</a></li><li><a class="nounderline abstract_t">Attwa E, Gharib K, Albalat W, Amer A. Classical Kaposi sarcoma: case reports with unusual presentation on the penis and scrotum. Int J Dermatol 2016; 55:e533.</a></li><li><a class="nounderline abstract_t">Colletti G, Allevi F, Moneghini L, Rabbiosi D. Bilateral auricular classic Kaposi's sarcoma. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87:146.</a></li><li><a class="nounderline abstract_t">DUTZ W, STOUT AP. Kaposi's sarcoma in infants and children. Cancer 1960; 13:684.</a></li><li><a class="nounderline abstract_t">Kalkan G, Akbay G, Gungor E, et al. A case of classic Kaposi sarcoma in a 11-year-old male. Indian J Dermatol Venereol Leprol 2011; 77:730.</a></li><li><a class="nounderline abstract_t">Jackson CC, Dickson MA, Sadjadi M, et al. Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. Pediatr Blood Cancer 2016; 63:392.</a></li><li><a class="nounderline abstract_t">Byun M, Abhyankar A, Lelarge V, et al. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J Exp Med 2010; 207:2307.</a></li><li><a class="nounderline abstract_t">Byun M, Ma CS, Akçay A, et al. Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med 2013; 210:1743.</a></li><li><a class="nounderline abstract_t">Mohanna S, Sanchez J, Ferrufino JC, et al. Lymphangioma-like Kaposi's sarcoma: report of four cases and review. J Eur Acad Dermatol Venereol 2006; 20:1010.</a></li><li><a class="nounderline abstract_t">RONCHESE F, KERN AB. Lymphangioma-like tumors in Kaposi's sarcoma. AMA Arch Derm 1957; 75:418.</a></li><li><a class="nounderline abstract_t">Pantanowitz L, Duke WH. Lymphoedematous variants of Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2008; 22:118.</a></li><li><a class="nounderline abstract_t">Megaly M, Boshra N. Pyogenic granuloma-like Kaposi's sarcoma. Lancet 2022; 399:e38.</a></li><li><a class="nounderline abstract_t">Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008; 3:31.</a></li><li><a class="nounderline abstract_t">Balachandra B, Tunitsky E, Dawood S, et al. Classic Kaposi's sarcoma presenting first with gastrointestinal tract involvement in a HIV-negative Inuit male--a case report and review of the literature. Pathol Res Pract 2006; 202:623.</a></li><li><a class="nounderline abstract_t">Zoubeidi H, Aydi Z, Daoud F, et al. Kaposi's Sarcoma Presenting as Lymphadenopathy in an Immunocompetent Patient. Eur J Case Rep Intern Med 2016; 3:000493.</a></li><li><a class="nounderline abstract_t">Ozbudak IH, Guney K, Mutlu D, et al. Bilateral tonsillar and esophageal Kaposi sarcoma in an HIV-negative patient. Ear Nose Throat J 2011; 90:E23.</a></li><li><a class="nounderline abstract_t">Neff R, Kremer S, Voutsinas L, et al. Primary Kaposi's sarcoma of the ileum presenting as massive rectal bleeding. Am J Gastroenterol 1987; 82:276.</a></li><li><a class="nounderline abstract_t">Weprin L, Zollinger R, Clausen K, Thomas FB. Kaposi's sarcoma: endoscopic observations of gastric and colon involvement. J Clin Gastroenterol 1982; 4:357.</a></li><li><a class="nounderline abstract_t">Stratigos JD, Potouridou I, Katoulis AC, et al. Classic Kaposi's sarcoma in Greece: a clinico-epidemiological profile. Int J Dermatol 1997; 36:735.</a></li><li><a class="nounderline abstract_t">Jaimovich L, Calb I, Kaminsky A. Kaposi's sarcoma of the conjunctiva. J Am Acad Dermatol 1986; 14:589.</a></li><li><a class="nounderline abstract_t">Cottoni F, Masala MV, Piras P, et al. Mucosal involvement in classic Kaposi's sarcoma. Br J Dermatol 2003; 148:1273.</a></li><li><a class="nounderline abstract_t">Kolios G, Kaloterakis A, Filiotou A, et al. Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS). Gastrointest Endosc 1995; 42:336.</a></li><li><a class="nounderline abstract_t">Pagani D, Bellinvia M, Capaccio P, et al. An unusual cause of a parotid mass in an immunocompetent host: classic Kaposi's sarcoma. Tumori 2009; 95:248.</a></li><li><a class="nounderline abstract_t">Caponetti G, Dezube BJ, Restrepo CS, Pantanowitz L. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients. Cancer 2007; 109:1040.</a></li><li><a class="nounderline abstract_t">Bordelon TR, Burton GV, Grafton WD, Mills GM. Kaposi's sarcoma involvement of the bone marrow. Am J Med Sci 1990; 300:383.</a></li><li><a class="nounderline abstract_t">Coll J, Pedro-Botet J, Pallas JO, et al. Classic Kaposi's sarcoma with pulmonary involvement in an HIV-negative woman. Clin Exp Dermatol 1995; 20:410.</a></li><li><a class="nounderline abstract_t">Brenner B, Rakowsky E, Katz A, et al. Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines. Int J Oncol 1999; 14:1097.</a></li><li><a class="nounderline abstract_t">Zurrida S, Bartoli C, Nolé F, et al. Classic Kaposi's sarcoma: a review of 90 cases. J Dermatol 1992; 19:548.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Kreuter A, Di Trolio R, et al. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol 2008; 128:1578.</a></li><li><a class="nounderline abstract_t">Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol 2008; 21:572.</a></li><li><a class="nounderline abstract_t">Potouridou I, Katsambas A, Pantazi V, et al. Classic Kaposi's sarcoma in two young heterosexual men. J Eur Acad Dermatol Venereol 1998; 10:48.</a></li><li><a class="nounderline abstract_t">Ohe EM, Padilha MH, Enokihara MM, et al. Fatal outcome in classic Kaposi's sarcoma. An Bras Dermatol 2010; 85:375.</a></li><li><a class="nounderline abstract_t">Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. [English translation from Archiv Für Dermatolgie Und Syphillis 1872; 4:265-273]. CA Cancer J Clin 1982; 32:342.</a></li><li class="breakAll">Yoon SS, Maki RG, Asare EA, et al. Soft tissue sarcoma of the trunk and extremities. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.507.</li><li class="breakAll">Maki RG, Folpe AL, Guadagnono BA, et al. Soft tissue sarcoma: Unusual histologies and sites. In: AJCC cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.539.</li><li><a class="nounderline abstract_t">Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol 2003; 13:83.</a></li><li><a class="nounderline abstract_t">Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine. Cancer 1994; 74:2873.</a></li><li><a class="nounderline abstract_t">Benajiba L, Lambert J, La Selva R, et al. Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Brambilla L, Tourlaki A, Ferrucci S, et al. Treatment of classic Kaposi's sarcoma-associated lymphedema with elastic stockings. J Dermatol 2006; 33:451.</a></li><li><a class="nounderline abstract_t">Trevisan F, Cunha PR, Pinto CA, Alves CA. Classic Kaposi's sarcoma treated with elastic stockings and outpatient follow-up of a 90-year-old patient. An Bras Dermatol 2013; 88:200.</a></li><li><a class="nounderline abstract_t">Weintraub CM, Skudowitz RB. Excision of 1,674 classic Kaposi's sarcomas. S Afr J Surg 2002; 40:80.</a></li><li><a class="nounderline abstract_t">Tourlaki A, Bellinvia M, Brambilla L. Recommended surgery of Kaposi's sarcoma nodules. J Dermatolog Treat 2015; 26:354.</a></li><li><a class="nounderline abstract_t">Tombolini V, Osti MF, Bonanni A, et al. Radiotherapy in classic Kaposi's sarcoma (CKS): experience of the Institute of Radiology of University "La Sapienza" of Rome. Anticancer Res 1999; 19:4539.</a></li><li><a class="nounderline abstract_t">Cooper JS, Sacco J, Newall J. The duration of local control of classic (non-AIDS-associated) Kaposi's sarcoma by radiotherapy. J Am Acad Dermatol 1988; 19:59.</a></li><li><a class="nounderline abstract_t">Nisce LZ, Safai B, Poussin-Rosillo H. Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma. Cancer 1981; 47:640.</a></li><li><a class="nounderline abstract_t">Stein ME, Lakier R, Spencer D, et al. Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1994; 28:613.</a></li><li><a class="nounderline abstract_t">Huang KM, Hsu CH, Cheng JC, et al. Radiotherapy of classic Kaposi's sarcoma in Taiwan, an area where classic Kaposi's sarcoma is not prevalent. Anticancer Res 2006; 26:4659.</a></li><li><a class="nounderline abstract_t">Chang LF, Reddy S, Shidnia H. Comparison of radiation therapy of classic and epidemic Kaposi's sarcoma. Am J Clin Oncol 1992; 15:200.</a></li><li><a class="nounderline abstract_t">Caccialanza M, Marca S, Piccinno R, Eulisse G. Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol 2008; 22:297.</a></li><li><a class="nounderline abstract_t">Yildiz F, Ozyar E, Uzal D, et al. Kaposi's sarcoma: the efficacy of a single fraction of 800 cGy. Dermatology 1997; 195:142.</a></li><li><a class="nounderline abstract_t">Hauerstock D, Gerstein W, Vuong T. Results of radiation therapy for treatment of classic Kaposi sarcoma. J Cutan Med Surg 2009; 13:18.</a></li><li><a class="nounderline abstract_t">Kirova YM, Belembaogo E, Frikha H, et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiother Oncol 1998; 46:19.</a></li><li><a class="nounderline abstract_t">Hamilton CR, Cummings BJ, Harwood AR. Radiotherapy of Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:1931.</a></li><li><a class="nounderline abstract_t">Weshler Z, Loewinger E, Loewenthal E, et al. Megavoltage radiotherapy using water bolus in the treatment of Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:2029.</a></li><li><a class="nounderline abstract_t">Tappero JW, Berger TG, Kaplan LD, et al. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 1991; 4:839.</a></li><li><a class="nounderline abstract_t">Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res 2001; 104:127.</a></li><li><a class="nounderline abstract_t">Webster GF. Local therapy for mucocutaneous Kaposi's sarcoma in patients with acquired immunodeficiency syndrome. Dermatol Surg 1995; 21:205.</a></li><li><a class="nounderline abstract_t">Chun YS, Chang SN, Park WH. A case of classical Kaposi's sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol 1999; 26:240.</a></li><li><a class="nounderline abstract_t">Marchell N, Alster TS. Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser. Dermatol Surg 1997; 23:973.</a></li><li><a class="nounderline abstract_t">Özdemir M, Balevi A. Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. Dermatol Surg 2017; 43:366.</a></li><li><a class="nounderline abstract_t">Vassallo C, Carugno A, Derlino F, et al. Intralesional vinblastine injections for treatment of classic Kaposi sarcoma in diabetic patients. Cutis 2015; 95:E28.</a></li><li><a class="nounderline abstract_t">Odom RB, Goette DK. Treatment of cutaneous Kaposi's sarcoma with intralesional vincristine. Arch Dermatol 1978; 114:1693.</a></li><li><a class="nounderline abstract_t">Brambilla L, Bellinvia M, Tourlaki A, et al. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 2010; 162:854.</a></li><li><a class="nounderline abstract_t">Mirza YA, Altamura D, Hirbod T, Verdolini R. Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report. Case Rep Dermatol 2015; 7:17.</a></li><li><a class="nounderline abstract_t">Trattner A, Reizis Z, David M, et al. The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma. Br J Dermatol 1993; 129:590.</a></li><li><a class="nounderline abstract_t">Curatolo P, Quaglino P, Marenco F, et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2012; 19:192.</a></li><li><a class="nounderline abstract_t">Di Monta G, Caracò C, Benedetto L, et al. Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma. Eur J Surg Oncol 2014; 40:61.</a></li><li><a class="nounderline abstract_t">Latini A, Bonadies A, Trento E, et al. Effective treatment of Kaposi's sarcoma by electrochemotherapy and intravenous bleomycin administration. Dermatol Ther 2012; 25:214.</a></li><li><a class="nounderline abstract_t">Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002; 138:542.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol 2006; 155:856.</a></li><li><a class="nounderline abstract_t">Célestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 2008; 58:585.</a></li><li><a class="nounderline abstract_t">Goiriz R, Ríos-Buceta L, De Arriba AG, et al. Treatment of classic Kaposi's sarcoma with topical imiquimod. Dermatol Surg 2009; 35:147.</a></li><li><a class="nounderline abstract_t">Alcántara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Vélez García-Nieto A. Classic Kaposi's sarcoma treated with topical 0.5% timolol gel. Dermatol Ther 2016; 29:309.</a></li><li><a class="nounderline abstract_t">Abdelmaksoud A, Filoni A, Giudice G, Vestita M. Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. J Am Acad Dermatol 2017; 76:153.</a></li><li><a class="nounderline abstract_t">Meseguer-Yebra C, Cardeñoso-Álvarez ME, Bordel-Gómez MT, et al. Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases. Br J Dermatol 2015; 173:860.</a></li><li><a class="nounderline abstract_t">Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 2012; 18:1201.</a></li><li><a class="nounderline abstract_t">McAllister SC, Hanson RS, Manion RD. Propranolol Decreases Proliferation of Endothelial Cells Transformed by Kaposi's Sarcoma-Associated Herpesvirus and Induces Lytic Viral Gene Expression. J Virol 2015; 89:11144.</a></li><li><a class="nounderline abstract_t">Zhang L, Mai HM, Zheng J, et al. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol 2014; 7:48.</a></li><li><a class="nounderline abstract_t">Brambilla L, Tourlaki A. Silver nitrate for Kaposi's sarcoma nodules: A new look at an old treatment. J Dermatolog Treat 2017; 28:152.</a></li><li><a class="nounderline abstract_t">Goedert JJ, Scoppio BM, Pfeiffer R, et al. Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial. J Eur Acad Dermatol Venereol 2008; 22:1101.</a></li><li><a class="nounderline abstract_t">Díaz-Ley B, Grillo E, Ríos-Buceta L, et al. Classic Kaposi's sarcoma treated with topical rapamycin. Dermatol Ther 2015; 28:40.</a></li><li><a class="nounderline abstract_t">Castiñeiras I, Almagro M, Rodríguez-Lozano J, et al. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin. J Dermatolog Treat 2006; 17:377.</a></li><li><a class="nounderline abstract_t">Di Lorenzo G, Di Trolio R, Montesarchio V, et al. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer 2008; 112:1147.</a></li><li><a class="nounderline abstract_t">Kreuter A, Rasokat H, Klouche M, et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 2005; 23:653.</a></li><li><a class="nounderline abstract_t">Potouridou I, Korfitis C, Ioannidou D, et al. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities. Br J Dermatol 2008; 158:431.</a></li><li><a class="nounderline abstract_t">Brambilla L, Labianca R, Ferrucci SM, et al. Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology 2001; 202:119.</a></li><li><a class="nounderline abstract_t">Brambilla L, Boneschi V, Fossati S, et al. Oral etoposide for Kaposi's Mediterranean sarcoma. Dermatologica 1988; 177:365.</a></li><li><a class="nounderline abstract_t">Brambilla L, Miedico A, Ferrucci S, et al. Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2006; 20:1090.</a></li><li><a class="nounderline abstract_t">Brambilla L, Romanelli A, Bellinvia M, et al. Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases. Br J Dermatol 2008; 158:1339.</a></li><li><a class="nounderline abstract_t">Chao SC, Lee JY, Tsao CJ. Treatment of classical type Kaposi's sarcoma with paclitaxel. Anticancer Res 2001; 21:571.</a></li><li><a class="nounderline abstract_t">Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 2006; 106:1785.</a></li><li><a class="nounderline abstract_t">Zustovich F, Lombardi G, Pastorelli D. Important role of gemcitabine in the treatment of classic Kaposi's sarcoma. Tumori 2009; 95:562.</a></li><li><a class="nounderline abstract_t">Zidan J, Robenstein W, Abzah A, Taman S. Treatment of Kaposi's sarcoma with vinblastine in patients with disseminated dermal disease. Isr Med Assoc J 2001; 3:251.</a></li><li><a class="nounderline abstract_t">Brambilla L, Labianca R, Fossati S, et al. Vinorelbine: an active drug in Mediterranean Kaposi’s sarcoma. Eur J Dermatol 1995; 5:467.</a></li><li><a class="nounderline abstract_t">Tas F, Sen F, Keskin S, Kilic L. Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS). J Eur Acad Dermatol Venereol 2013; 27:789.</a></li><li><a class="nounderline abstract_t">Zustovich F, Ferro A, Toso S. Gemcitabine for the treatment of classic Kaposi's Sarcoma: a case series. Anticancer Res 2013; 33:5531.</a></li><li><a class="nounderline abstract_t">Brambilla L, Recalcati S, Tourlaki A. Vinorelbine therapy in classic Kaposi's sarcoma: a retrospective study of 20 patients. Eur J Dermatol 2015; 25:535.</a></li><li><a class="nounderline abstract_t">Krown SE, Moser CB, MacPhail P, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet 2020; 395:1195.</a></li><li><a class="nounderline abstract_t">Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010; 116:3969.</a></li><li><a class="nounderline abstract_t">Polizzotto MN, Uldrick TS, Wyvill KM, et al. Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. J Clin Oncol 2016; 34:4125.</a></li><li><a class="nounderline abstract_t">Ramaswami R, Polizzotto MN, Lurain K, et al. Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clin Cancer Res 2022; 28:840.</a></li><li class="breakAll">US Food and Drug Administration Label for Pomalidomide. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204026s023lbl.pdf (Accessed on May 19, 2020).</li><li><a class="nounderline abstract_t">Rescigno P, Di Trolio R, Buonerba C, et al. Non-AIDS-related Kaposi's sarcoma: A single-institution experience. World J Clin Oncol 2013; 4:52.</a></li><li><a class="nounderline abstract_t">Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013; 68:313.</a></li><li><a class="nounderline abstract_t">Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001; 13:374.</a></li><li><a class="nounderline abstract_t">Rubegni P, Sbano P, De Aloe G, et al. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology 2007; 215:240.</a></li><li><a class="nounderline abstract_t">Ben M'barek L, Fardet L, Mebazaa A, et al. A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. Dermatology 2007; 215:202.</a></li><li><a class="nounderline abstract_t">Krown SE. AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa? Cytokine Growth Factor Rev 2007; 18:395.</a></li><li><a class="nounderline abstract_t">Costa da Cunha CS, Lebbe C, Rybojad M, et al. Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol 1996; 132:285.</a></li><li><a class="nounderline abstract_t">Monini P, Sgadari C, Grosso MG, et al. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009; 23:534.</a></li><li><a class="nounderline abstract_t">Taddeo A, Presicce P, Brambilla L, et al. Circulating endothelial progenitor cells are increased in patients with classic Kaposi's sarcoma. J Invest Dermatol 2008; 128:2125.</a></li><li><a class="nounderline abstract_t">Guenova E, Metzler G, Hoetzenecker W, et al. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 2008; 144:692.</a></li><li><a class="nounderline abstract_t">Merimsky O, Jiveliouk I, Sagi-Eisenberg R. Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma. Sarcoma 2008; 2008:825093.</a></li><li><a class="nounderline abstract_t">Mourah S, Porcher R, Battistella M, et al. Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma. Br J Dermatol 2015; 173:1284.</a></li><li><a class="nounderline abstract_t">Harris BHL, Walsh JL, Neciunaite R, et al. Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy. Clin Exp Dermatol 2018; 43:234.</a></li><li><a class="nounderline abstract_t">Genovese G, Venegoni L, Fanoni D, et al. PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma. J Eur Acad Dermatol Venereol 2019; 33:e269.</a></li><li><a class="nounderline abstract_t">Paydas S, Bagir EK, Deveci MA, Gonlusen G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol 2016; 33:93.</a></li><li><a class="nounderline abstract_t">Beldi-Ferchiou A, Lambert M, Dogniaux S, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 2016; 7:72961.</a></li><li><a class="nounderline abstract_t">Saller J, Walko CM, Millis SZ, et al. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. J Natl Compr Canc Netw 2018; 16:797.</a></li><li><a class="nounderline abstract_t">Delyon J, Biard L, Renaud M, et al. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncol 2022; 23:491.</a></li><li><a class="nounderline abstract_t">Galanina N, Goodman AM, Cohen PR, et al. Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res 2018; 6:1129.</a></li><li><a class="nounderline abstract_t">Delyon J, Bizot A, Battistella M, et al. PD-1 blockade with nivolumab in endemic Kaposi sarcoma. Ann Oncol 2018; 29:1067.</a></li><li><a class="nounderline abstract_t">Rajdev L, Lensing S, Ramos JC, et al. 1023MO AMC 095: A report of nivolumab (nivo) in advanced HIV associated solid tumours (ST). Ann Oncol 2020; 31;4S.</a></li><li><a class="nounderline abstract_t">Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol 2019; 5:1049.</a></li><li><a class="nounderline abstract_t">Zer A, Icht O, Yosef L, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann Oncol 2022; 33:720.</a></li><li class="breakAll">You H, Asiimwe S, Byakwaga H, et al. Low prevalence of KSHV DNA in female genital fluid: Findings from Zimbabwean women and systematic review of the literature of KSHV shedding in body fluids and mucous membrane surfaces. Abstract presentation, 16th International Conference on Malignancies in HIV/AIDS, Bethesda, MD, October 2017. p.115.</li><li><a class="nounderline abstract_t">Butler LM, Osmond DH, Jones AG, Martin JN. Use of saliva as a lubricant in anal sexual practices among homosexual men. J Acquir Immune Defic Syndr 2009; 50:162.</a></li></ol></div><div id="topicVersionRevision">Topic 7729 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8657239" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8705864" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521982" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sexual transmission and the natural history of human herpesvirus 8 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1967458" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Kaposi's sarcoma in HIV-negative homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525262" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Kaposi's sarcoma in HIV-negative men having sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814464" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Kaposi sarcoma in HIV-negative men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29377280" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A fifth subtype of Kaposi's sarcoma, classic Kaposi's sarcoma in men who have sex with men: a cohort study in Paris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33584957" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Kaposi Sarcoma of the Medial Foot in an MSM, HIV-Negative Man: A Fifth Clinical Variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27231143" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Classical Kaposi sarcoma: case reports with unusual presentation on the penis and scrotum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24014559" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bilateral auricular classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334644" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Kaposi's sarcoma: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13818924" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Kaposi's sarcoma in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016293" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A case of classic Kaposi sarcoma in a 11-year-old male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26469702" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876309" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897980" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16922960" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lymphangioma-like Kaposi's sarcoma: report of four cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13402216" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lymphangioma-like tumors in Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181991" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lymphoedematous variants of Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26498707" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pyogenic granuloma-like Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18655700" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Histological variants of cutaneous Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682127" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Classic Kaposi's sarcoma presenting first with gastrointestinal tract involvement in a HIV-negative Inuit male--a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30755897" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Kaposi's Sarcoma Presenting as Lymphadenopathy in an Immunocompetent Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21792787" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bilateral tonsillar and esophageal Kaposi sarcoma in an HIV-negative patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3493686" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary Kaposi's sarcoma of the ileum presenting as massive rectal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7119413" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kaposi's sarcoma: endoscopic observations of gastric and colon involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9372346" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Classic Kaposi's sarcoma in Greece: a clinico-epidemiological profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3958274" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Kaposi's sarcoma of the conjunctiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828767" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mucosal involvement in classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8536903" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Gastroscopic findings in Mediterranean Kaposi's sarcoma (non-AIDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19579875" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : An unusual cause of a parotid mass in an immunocompetent host: classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17265518" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Kaposi sarcoma of the musculoskeletal system: a review of 66 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2264577" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Kaposi's sarcoma involvement of the bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8593719" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Classic Kaposi's sarcoma with pulmonary involvement in an HIV-negative woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10339664" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1479113" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Classic Kaposi's sarcoma: a review of 90 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18185536" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376387" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552757" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Classic Kaposi's sarcoma in two young heterosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20676474" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fatal outcome in classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Idiopathic multiple pigmented sarcoma of the skin. [English translation from Archiv Für Dermatolgie Und Syphillis 1872; 4:265-273]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Idiopathic multiple pigmented sarcoma of the skin. [English translation from Archiv Für Dermatolgie Und Syphillis 1872; 4:265-273]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Idiopathic multiple pigmented sarcoma of the skin. [English translation from Archiv Für Dermatolgie Und Syphillis 1872; 4:265-273]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12609790" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7954250" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mediterranean Kaposi's sarcoma in the elderly. A randomized study of oral etoposide versus vinblastine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34063894" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16848816" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Treatment of classic Kaposi's sarcoma-associated lymphedema with elastic stockings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24346919" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Classic Kaposi's sarcoma treated with elastic stockings and outpatient follow-up of a 90-year-old patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12162235" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Excision of 1,674 classic Kaposi's sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25283737" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recommended surgery of Kaposi's sarcoma nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650807" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Radiotherapy in classic Kaposi's sarcoma (CKS): experience of the Institute of Radiology of University "La Sapienza" of Rome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3403746" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The duration of local control of classic (non-AIDS-associated) Kaposi's sarcoma by radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6784910" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113104" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17214323" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Radiotherapy of classic Kaposi's sarcoma in Taiwan, an area where classic Kaposi's sarcoma is not prevalent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1590271" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of radiation therapy of classic and epidemic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18269597" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310721" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Kaposi's sarcoma: the efficacy of a single fraction of 800 cGy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298767" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Results of radiation therapy for treatment of classic Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9488122" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3771313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Radiotherapy of Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3095276" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Megavoltage radiotherapy using water bolus in the treatment of Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895204" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11191125" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7712086" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Local therapy for mucocutaneous Kaposi's sarcoma in patients with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343470" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A case of classical Kaposi's sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9357509" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28157730" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26057517" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intralesional vinblastine injections for treatment of classic Kaposi sarcoma in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/718222" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment of cutaneous Kaposi's sarcoma with intralesional vincristine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995366" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25848347" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-Term Response of Classic Kaposi's Sarcoma to Intralesional Doxorubicin: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8251357" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The therapeutic effect of intralesional interferon in classical Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21822561" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075826" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Electrochemotherapy as "new standard of care" treatment for cutaneous Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22741941" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effective treatment of Kaposi's sarcoma by electrochemotherapy and intravenous bleomycin administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11939830" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Topical 0.1% alitretinoin gel for classic Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16965450" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068265" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19076206" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatment of classic Kaposi's sarcoma with topical imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27329079" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Classic Kaposi's sarcoma treated with topical 0.5% timolol gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986137" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25704866" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22186256" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Molecular pathways: beta-adrenergic signaling in cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26269192" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Propranolol Decreases Proliferation of Endothelial Cells Transformed by Kaposi's Sarcoma-Associated Herpesvirus and Induces Lytic Viral Gene Expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24427325" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27425417" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Silver nitrate for Kaposi's sarcoma nodules: A new look at an old treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18384551" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25314592" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Classic Kaposi's sarcoma treated with topical rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17853313" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18098221" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377582" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18067475" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306832" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Treatment of classical Kaposi's sarcoma with gemcitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2466707" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Oral etoposide for Kaposi's Mediterranean sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987264" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Combination of vinblastine and bleomycin as first line therapy in advanced classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363766" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11299806" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment of classical type Kaposi's sarcoma with paclitaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534786" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19856679" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Important role of gemcitabine in the treatment of classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344835" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of Kaposi's sarcoma with vinblastine in patients with disseminated dermal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Vinorelbine: an active drug in Mediterranean Kaposi’s sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188463" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Oral etoposide as first-line therapy in the treatment of patients with advanced classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24324093" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Gemcitabine for the treatment of classic Kaposi's Sarcoma: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26552718" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Vinorelbine therapy in classic Kaposi's sarcoma: a retrospective study of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145827" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20564162" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27863194" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34862247" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34862247" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23696963" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Non-AIDS-related Kaposi's sarcoma: A single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22695100" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Treatments for classic Kaposi sarcoma: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11555715" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Management of Kaposi sarcoma: the role of interferon and thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17823523" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Thalidomide in the treatment of Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17823515" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17656146" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607632" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Long-term follow-up of non-HIV Kaposi's sarcoma treated with low-dose recombinant interferon alfa-2b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19169139" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305570" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Circulating endothelial progenitor cells are increased in patients with classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18490609" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18509482" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970141" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282751" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Ring a ring o'roses, a patient with Kaposi's? Pazopanib, pazopanib, it might go away. Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30835883" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421997" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27662664" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30006421" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35279271" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30194084" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29324995" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : PD-1 blockade with nivolumab in endemic Kaposi sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : 1023MO AMC 095: A report of nivolumab (nivo) in advanced HIV associated solid tumours (ST)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730549" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35339649" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35339649" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131893" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Use of saliva as a lubricant in anal sexual practices among homosexual men.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
